NCT06379646View on ClinicalTrials.gov

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

NARecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

April 21, 2025

Study Completion Date

April 21, 2026

Conditions
Systemic Lupus ErythematosusSystemic SclerosisInflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntiphospholipid SyndromeSjogren's Syndrome
Interventions
OTHER

YTS109

Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

lead

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY